Artificially controlled degradable inorganic nanomaterial for cancer theranostics.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27768974.
- Also identified by DOI 10.1016/j.biomaterials.2016.10.028.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Multifunctional nanomaterials for cancer diagnosis and therapy have recently prompted widespread concern. To avoid nanotoxicity, the development of novel degradable functional materials must be our main focus. In this study, we firstly developed ethylenediaminetetraacetic acid calcium disodium salt (EDTA)- and bovine serum albumin (BSA)-capped Mn<sub>3</sub>O<sub>4</sub> nanoparticles (MONPs-BSA-EDTA) as a novel inorganic nanomaterials for multifunctional imaging-guided photothermal therapy, which can be degraded in a progress-controlled way by artificially introduced ascorbic acid. The degradation products can also be captured and their excretion accelerated. Careful studies suggested that the toxicity of the MONPs-BSA-EDTA and its degradation products is low. The degradation mechanism also suggests a new method of controlled drug release. The development of artificially controlled degradable inorganic nanomaterials also provides a new way to degrade nanomaterials and minimize ion release, which may have potential applications in cancer theranostics without nanotoxicity.
Medical subject headings
- Delayed-Action Preparations
- Drug Implants
- Nanocapsules
- Neoplasms, Experimental
- Theranostic Nanomedicine